Latest News Archive

Please select Category, Year, and then Month to display items

Aligning African values with modern gender equality perspectives

19 September 2023 | Story Valentino Ndaba | Photo Unsplash

As we reflect on the significance of Women's Month, which occurred last month, it is worth noting that the Gender Equality and Anti-Discrimination Office (GEADO) at the University of the Free State (UFS) organised a thought-provoking seminar titled, "Bridging the gap: Exploring the Intersection of Traditional African values and Modern Perspectives in Achieving Gender Equality." This event, featuring distinguished guest speakers Prof Nokuzola Mndende and Dr Munyaradzi Mushonga, delved into the historical context of traditional African values and their impact on gender roles and norms. Their primary objective was to discern strategies for fostering dialogue, understanding, and collaboration between traditional and modern stakeholders, all in the noble pursuit of advancing gender equality in Africa.

Tradition versus Modernity

Prof Nokuzola Mndende, an adjunct professor in the Department of Sociology and Anthropology at Nelson Mandela University, as well as the President of We Come Back Spirituality and Founder of Icamagu Heritage Institute, emphasised the importance of African scholars embracing their roots. She stated, "It is important that young African scholars must be bold and change direction and start from home using African tools. In their endeavour to decoloniality, they must not forget their past." She also stressed the need to discard Western theories and spectacles that have been imposed, highlighting the scarcity of literature that portrays the positive aspects of African customs.

Dr Mushonga, the Programme Director for Africa Studies at the UFS Centre for Gender and Africa Studies, drew attention to the impact of modernity on a global scale. He referred to the 1500s when the world was pluricentric, as opposed to the current Eurocentric world order. Dr Mushonga cautioned against the seductive allure of modernity, which tends to cast African traditional perspectives as regressive while promoting Eurocentric ones as progressive.

Fostering equality in Africa

Siyanda Magayana, Senior Officer at the Gender Equality and Anti-Discrimination Office, shed light on the webinar's purpose. She explained, "the webinar intended to critically engage whether there is a gap between African traditional perspectives and values of gender equality against modern perspectives. In addition, we wanted to examine the emergence of modern perspectives and their influence in challenging gender inequality in an African context." She further highlighted the need for African institutions to adopt context-specific approaches to gender equality, rather than relying on Eurocentric models.

Magayana also echoed Prof Mndende's preference for the term "gender equity" over "gender equality," as the latter can inadvertently reinforce a perception of male superiority. Magayana emphasised that achieving gender equity in African contexts should deviate from Eurocentric perspectives, considering the unique histories, understandings, and people in the Global South.

Breaking the glass ceiling

As a prelude to the seminar, GEADO also hosted a webinar in honour of Women’s Month titled "Breaking the Glass Ceiling in Higher Education.” This webinar shed light on the unique challenges women face in academia, addressing implicit biases, stereotypes, and gender-based discrimination. It provided a platform for women to share their triumphs and experiences. Together, these initiatives propel us towards a future marked by diverse leadership and empowered strategies, ultimately promoting gender equality on the continent.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept